107results about How to "Effective prevention and treatment" patented technology

The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and / or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.

The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and / or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.

The present invention provides a compound that has an excellent inhibitory activity on STAT6 activation and is effective against allergic diseases, and a medicinal composition thereof. According to the present invention, disclosed is the compound represented by the General Formula (I) [where R1 and R2 independently represent a C1-6 alkyl group and the like that may have a hydrogen atom or a substituent; R3 represents a C1-6 alkyl group and the like that may have a substituent; R4 and R5 independent represents a hydrogen atom or a C1-6 alkyl group and the like that may have a substituent; R6 represents a hydrogen atom and the like; W represents —SO2— and the like; and X represents a sulphur atom and the like.]or a salt thereof, or a hydrate thereof.

Disclosed is an agent for reducing visceral fat, which comprises a cell of a lactic acid bacterium, particularly a lactic acid bacterium belonging to the genus Lactobacillus or Lactococcus and / or a culture of the cell as an active ingredient. The agent can ameliorate the disease condition of metabolic syndrome which is a combination of risk factors including hypertension, hyperlipemia, impaired glucose tolerance and the like, and can also reduce the accumulation of visceral fat. Further disclosed is a food / beverage or feed comprising the agent.

The present invention discloses a method for the preparation of a protein peptide, peptide powder prepared thereby, and use of the peptide powder in hypouricemic food products or health care products. The peptide powder is capable of inhibiting the activity of xanthine oxidase and effectively reducing uric acid. The method in an example of the present invention comprises: mincing the tuna, heating with steam or water to obtain a pretreated tuna, enzymolysing the pretreated tuna, deactivating the enzyme, centrifuging, removing impurities to obtain a supernatant, concentrating, and drying to obtain the peptide powder of interest.

The invention discloses a composition comprising at least one N-acetyl-lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, for use in the prevention and / or treatment of skin conditions and skin diseases. Preferably said composition is a starter infant formula. Said skin disease is in particular atopic dermatitis.

An indenone derivative of formula (1) is effective in enhancing the activity of osteoblastic cells and inhibiting bone resorption by osteoclastic cells, and a pharmaceutical composition comprising the indenone derivative or a pharmaceutically acceptable salt thereof is useful for preventing or treating bone diseases such as osteoporosis.

The invention relates to a veterinary traditional Chinese medicine for treating fish diseases. The medicine is characterized by comprising the following components in parts by weight: 5-10 parts of folium isatidis, 4-8 parts of coptis chinensis, 6-12 parts of folium cortex eucommiae, 2-6 parts of Chinese Gall, 3-7 parts of acorus calamus, 8-15 parts of gingko leaf, 2-6 parts of pomegranate bark, 4-10 parts of scutellaria baicalensis, 8-15 parts of felwort, 3-8 parts of radix sophorae flavescentis, 6-12 parts of radix bupleuri, 5-10 parts of rheum officinale and 4-9 parts of common andrographis herb. The compound traditional Chinese medicine is synergetic and complementary in medicinal materials, has the effects of resisting bacteria, virus, bacterial endotoxin, fungus and parasite, improving immunity and promoting fish body growth and development, can simultaneously act on multiple targets of multiple diseases of fish, can be used for effectively preventing and treating hemorrhagic disease, septicemia, sepsis and other diseases caused by pathogenic bacterium / or bacterial products (such as bacterial endotoxin), parasite, virus and the like, and has remarkable preventing and treating effects on fish composite infectious diseases caused by multiple infectious agents.

Our objective is to provide a novel lipid metabolism-improving reagent effective in preventing and treating hyperlipidemia and obesity and to provide this reagent in food, beverages, nutritional supplements, and fodders with the ability to improve lipid metabolism. The whey protein hydrolysate as the active ingredient in the lipid metabolism-improving reagent has a molecular weight distribution of 10 kDa or less, with the main peak between 200 Da to 3 kDa, average peptide chain length (APL) of 2-8, free amino acid content of 20% or less, antigenicity of 1 / 10,000 or less compared with that of β-lactoglobulin.

The present invention provides a compound that has an excellent inhibitory activity on STAT6 activation and is effective against allergic diseases, and a medicinal composition thereof. According to the present invention, disclosed is the compound represented by the General Formula (I)[where R1 and R2 independently represent a C1-6 alkyl group and the like that may have a hydrogen atom or a substituent;R3 represents a C1-6 alkyl group and the like that may have a substituent;R4 and R5 independent represents a hydrogen atom or a C1-6 alkyl group and the like that may have a substituent;R6 represents a hydrogen atom and the like;W represents —SO2—and the like; andX represents a sulphur atom and the like.]or a salt thereof, or a hydrate thereof.

The invention discloses a composition comprising oligosaccharide, for use in the prevention and / or treatmentof skin conditions and / or skin diseases by increasing SCFA, in particular colonic propionate and butyrate. Said skin disease is in particular atopic dermatitis.

Provided is a method capable of effectively treating various diseases associated with energy excess, such as obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, via elevation of an NAD(P)+ / NAD(P)H ratio by increasing an NAD(P)+ concentration in vivo or in vitro through use of NAD(P)H as a substrate or coenzyme by oxidoreductase such as NAD(P)H:quinone oxidoreductase (NQO1), a method of screening a drug for the same and a therapeutic drug.

The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient.

The invention discloses a composition comprising at least one N-acetyl-lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, for use in the prevention and / or treatment of skin conditions and skin diseases. Preferably said composition is a starter infant formula. Said skin disease is in particular atopic dermatitis.

The present invention relates to a liquid pharmaceutical composition containing an N-phenylpyrazole derivative as active ingredient and alpha-(tetrahydrofuranyl)-omega-hydroxypoly(oxy-1,2-ethanediyl) as solvent for the treatment and / or prevention of infestations with fleas in domestic animals.

The present invention relates to an antibody binding to the domain 2 of human intercellular adhesion molecules-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and induce antigen-specific T cell tolerance, thereby be effective in the prevention and / or treatment of T cell-mediated immune disorders such as transplantation rejection, graft-versus-host disease, and autoimmune disease. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.

The present invention relates to a composition containing beta-glucan as an effective ingredient for prevention and treatment of osteoporosis. The above captioned beta-glucan is preferably the beta-1.3 / 1.6 glucan having a lactic acid as a substituent and this beta-1.3 / 1.6 glucan is preferably produced from Auerobasidium pullulans SM2001(KCCM 10307).

A method for preventing or treating porcine epidemic diarrhea, the method including: administering a live vaccine of a porcine epidemic diarrhea virus and an adjuvant to a pig through oral administration or nasal administration; and administering an inactivated vaccine of the porcine epidemic diarrhea virus and an adjuvant to the pig through intramuscular administration.

The present invention provides an energy emission device comprising: one or a plurality of energy emission means for emitting at least one type of energy selected from the group consisting of an electromagnetic wave or an electromagnetic stimulation, an elastic wave, an oscillatory wave and heat to at least one position of a subject selected from the group consisting of the brain, the spinal cord, the cerebrospinal fluid or the flow passage thereof and the brain cell interstitial fluid or the flow passage thereof; an energy controlling means for controlling an amount of energy emitted from the energy emission means; and a means for obtaining information relating to wakefulness and / or a sleeping state of the subject, in which the energy controlling means controls the amount of energy emitted depending on the information relating to the wakefulness and / or the sleeping state.

The present invention is intended to provide a pharmaceutical product for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the present invention is also intended to provide a preventive and / or therapeutic agent for various diseases based on inhibition of expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and the present invention relates to an agent for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and relates also to a preventive and / or therapeutic agent for various diseases based on the inhibition of the expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the agent comprising a compound represented by Formula (I), its salt, or a solvate of any of them as an active ingredient:wherein the symbols are the same as those given in the description.

The invention belongs to the field of medicine healthcare products and particularly relates to a medicine composition for treating osteoarthritis and a preparing technology thereof. The medicine composition for treating osteoarthritis is mainly prepared from, by weight, 20-45 parts of glucosamine and 4-20 parts of taurine. Preferably, the medicine composition is used in the mode that 140-670 weight parts of deionized water are added for supporting an oral liquid preparation; meanwhile, a pH value of oral liquid is 2.0-6.5 preferably. The medicine composition has the advantages of being good in stability, and remarkable in effect of treating osteoarthritis and especially senile osteoarthritis; moreover, the oral liquid preparation provided correspondingly has the above advantages and also has the advantages of reducing gastrointestinal pressure of patients and being easy to take and accept by the patients for a long term.

The invention discloses a preparation method of drinking water for control of rabbit dysentery. The drinking water is mainly formed by mixing of the following raw materials by weight part: 3-5 of Chinese herbal extracted liquid, 5-8 of beet juice, 10-30 of brown sugar, 0.5-1 of salt, and 800-1200 of water. Specifically, the Chinese herbal extracted liquid is obtained by extraction of the following crude drugs by weight part: 5-7 of Pycnonotus sinensis, 6-10 of root of kudzu vine, 5-7 of radix paeoniae alba, 6-10 of Chinese angelica, 2-4 of radix aucklandiae, 1-3 of cinnamon, 2-4 of betel nut, 12-18 of Chinese yam, 7-9 of lotus seed, 7-9 of forsythia, 7-9 of Viola philippica, 7-9 of dandelion, 4-6 of Scutellaria baicalensis, 2-4 of phellodendron, 8-12 of bighead atractylodes rhizome, 8-12 of Poria cocos, 5-7 of Alisma plantago-aquatica, 8-12 of semen coicis, 10-15 of licorice, 2-4 of Coptis chinensis, 8-12 of radix astragali, and 12-18 of jujube.

A method of treating preeclampsia including administering a therapeutically effective dose of resibufagenin to a patient having preeclampsia. Effecting the determination of the presence of preeclampsia may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does exist, concluding that preeclampsia does exist. The method may advantageously be practiced by employing urine, blood serum or blood plasma as the body specimen containing the protein in determining whether a patient has preeclampsia. In another embodiment, bufodienolide derivatives other than resibufagenin may be employed in lieu of thereof or in combination therewith. In another embodiment, resibufagenin analogues may be employed in the treatment of preeclampsia.

The invention provides a boiler four-tube abrasion-resistant anti-explosion three-dimensional monitoring system which comprises a three-dimensional modeling system and a data exchange system. The three-dimensional modeling system carries out model design and modeling on a four-tube device needing to be monitored and directly displays three-dimensional images through a displayer. The data exchange system enables monitoring data, an internal database, a four-tube abrasion-resistant anti-explosion data platform and a three-dimensional client of the four-tube device to be in communication connection with a management console, so that data are shared, data analysis results are reflected on a three-dimensional model, and accordingly defect observation and pre-warning display can be visually carried out.

The present invention is to provide a preventive or therapeutic agent for a neurodegenerative disease or a cognitive dysfunction, containing a compound represented by a following formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.

A method of treating preeclampsia including administering a therapeutically effective dose of resibufagenin to a patient having preeclampsia. Effecting the determination of the presence of preeclampsia may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does exist, concluding that preeclampsia does exist. The method may advantageously be practiced by employing urine, blood serum or blood plasma as the body specimen containing the protein in determining whether a patient has preeclampsia. In another embodiment, bufodienolide derivatives other than resibufagenin may be employed in lieu of thereof or in combination therewith. In another embodiment, resibufagenin analogues may be employed in the treatment of preeclampsia.

A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

The invention discloses children mouthwash containing a cymene bacteriostatic agent and a preparation method of the children mouthwash. The children mouthwash is prepared from the following materials:a traditional Chinese medicine extract, water, a bacteriostatic agent and sodium chloride, the traditional Chinese medicine extract comprises a caries prevention component, an internal heat clearingand inflammation diminishing component and a tooth strengthening component, the water is deionized water prepared by an RO reverse osmosis method, the bacteriostatic agent is o-cymene-5-ol, based on the total weight of 100%, the mouthwash comprises the following components in percentage by weight: 35% of the traditional Chinese medicine extract, 60% of the water, 4% of the bacteriostatic agent and1% of sodium chloride, the caries prevention component in the traditional Chinese medicine extract comprises green tea, the internal heat clearing and inflammation diminishing component comprises honeysuckle flower, menthae haplocalycis herba, stevia rebaudiana, momordica grosvenori, propolis, aloe and radix rhizoma glycyrrhizae, and the tooth strengthening component comprises alpiniae oxyphyllaefructus, schisandrae chinensis fructus, folium nelumbinis, pericarpium zanthoxyli and angelicae dahuricae radix. The children mouthwash containing the cymene bacteriostatic agent has the effects of clearing internal heat, diminishing inflammation and strengthening teeth, does not have any side effect, and can be used for effectively preventing and treating oral diseases such as dental caries andoral inflammation of children.

The present invention relates to the use of 6-(benzyl-amino)-2(S)-[[1-(hydroxymethyl) propyl]amino]-9-isopropylpurine) or at least one of its pharmaceutical acceptable salts for manufacturing a medication intended for the prevention and / or treatment of neurological diseases, in particular associated with neurological lesions.